Story perspectives

New Combo Therapy Delays Advanced Prostate Cancer Progression

10/21/2025

Summary

Story summary

The Phase III AMPLITUDE trial presented at the 2025 ESMO Congress shows that niraparib plus abiraterone acetate and prednisone significantly delays disease progression in men with advanced prostate cancer carrying homologous recombination repair (HRR) gene alterations.
The trial enrolled 696 men in 32 countries and showed stronger results in BRCA1 or BRCA2 mutations.
The PETRANHA trial assesses saruparib with androgen receptor pathway inhibitors in similar patients.

1 of 1

Story summary

The Phase III AMPLITUDE trial presented at the 2025 ESMO Congress shows that niraparib plus abiraterone acetate and prednisone significantly delays disease progression in men with advanced prostate cancer carrying homologous recombination repair (HRR) gene alterations.
The trial enrolled 696 men in 32 countries and showed stronger results in BRCA1 or BRCA2 mutations.
The PETRANHA trial assesses saruparib with androgen receptor pathway inhibitors in similar patients.